Avalo-Final_Black-01.jpg
Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference
February 07, 2022 16:01 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo-Final_Black-01.jpg
Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer
January 10, 2022 19:59 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo” or the “Company”), a leading clinical-stage precision medicine company that...
Avalo-Final_Black-01.jpg
Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event
January 06, 2022 07:30 ET | Avalo Therapeutics
Immunology portfolio highlighted by success of a second positive study with AVTX-002 further validates the LIGHT mechanism of action in inflammatory diseasesEfficacy signal demonstrated in heavily...
Avalo-Final_Black-01.jpg
Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022
December 16, 2021 07:30 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo-Final_Black-01.jpg
Avalo Appoints Two New Independent Directors to Its Board
December 06, 2021 07:30 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo-Final_Black-01.jpg
Avalo to Present at Two Upcoming Conferences
November 11, 2021 07:00 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo-Final_Black-01.jpg
Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 09, 2021 16:01 ET | Avalo Therapeutics
Topline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected in the fourth quarter of 2021Multiple data readouts across programs anticipated within the next six...
Avalo-Final_Black-01.jpg
Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
October 13, 2021 07:00 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo-Final_Black-01.jpg
Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 20, 2021 07:00 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo-Final_Black-01.jpg
Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
September 17, 2021 09:11 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that...